Embargo Watch

Keeping an eye on how scientific information embargoes affect news coverage

PNAS early embargo “break” total rises to nine for the year

leave a comment »

pnas juneThe Proceedings of the National Academy of Sciences (PNAS), which lifted the embargo on papers early 11 times last year because of breaks or previous media coverage, is on track for a similar figure this year, thanks to three recent incidents.

On October 27 the journal sent this to its media list:

Due to prior news coverage, PNAS is releasing the following Perspective without embargo. A link to the published article is below:


Accelerating scientific publication

According to a Perspective, publishing a scientific study in biology requires more data and time now than in the past, and efforts to reverse this trend may be needed to reduce the duration of scientific training and streamline the exchange of scientific findings in the life sciences.

Article #15-11912: “Accelerating scientific publication in biology,” by Ronald D. Vale.

The previous news coverage was in Insider Higher Ed and Slate, PNAS tells us. It was in fact of a preprint of Vale’s paper, which our sister blog, Retraction Watch, mentioned in a Slate piece, too.

A day later, on October 28, this went out to the PNAS media list:

PNAS is lifting the embargo early on the following paper. All other articles are under the scheduled embargo:

Article #15-14748: “Role of HIV-1 matrix protein p17 variants in Lymphoma Pathogenesis,” by Riccardo Dolcetti et al.

This time, it was more of a typical break, the journal tells us:

We found a story published in the below outlet prior to the embargo date. We are investigating the circumstances of the break.

The story appeared in Ansa.it.

And on November 10, this was the message:

Due to prior news coverage, PNAS is releasing the following article without embargo. A link to the published article is below:


Engineering small protein cancer therapeutics

Researchers describe high-affinity variants of the protein PD-1 engineered as small protein therapeutics for cancer immunotherapy that were more effective than an antibody at suppressing growth of large tumors in mice, and that could also be used as PET-based diagnostic agents to detect the immunotherapy target PD-L1 in tumors.

Article #15-19623: “Engineering high-affinity PD-1 variants for optimized immunotherapy and immunoPET imaging,” by Roy L. Maute et al.

The previous coverage, PNAS tells us, was a press release from American Association for Cancer Research about a presentation in September.

The journal has lifted the embargo early six other times this year.


Written by Ivan Oransky

November 16, 2015 at 10:00 am

Posted in Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: